SPECIAL NOTICE

We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

InvestoGain Australia

Celebrating 20 Years in Business

Thank you for being part of our development since September 2001. With your ongoing support we look forward to many exciting developments ahead.

SEARCH LISTED COMPANY


Any AUS or NZ company

BROWSE

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

PROTEOMICS INTERNATIONAL LABORATORIES LTD (PIQ)

Click here for free access to this company's:
ASX, Legal & CGT Status

SHARE PRICES

(updated at weekends)

Former (or subsequent) names

 

Shareholder links

Our website ranking of PIQ: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Automic Registry Services Level 5, 126 Phillip Street Sydney NSW 2000

Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
Fax :
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000PIQ0
Address: Suite 13, The Atrium, 123A Colin Street, WEST PERTH, WA, AUSTRALIA, 6005
Tel:  +61 8 9389 1992 Fax: +61 8 6151 1038

Date first listed: 16/04/2015
Company Secretary: Ms Karen Logan
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: 

News & Events

Expand this box to read and print

The suspension of trading in the securities of Proteomics International Laboratories Ltd will be lifted from the commencement of trading on Monday, 5 July 2021, following the release by PIQ of an announcement regarding a presentation given at the American Diabetes Association's 81st Scientific Sessions, 25-29 June 2021.

02/07/2021

Proteomics International Laboratories Ltd refers to its ASX release of 25 June 2021 titled "Modelling shows PromarkerD could save US payers $384 billion". Following consultation with ASX, and to ensure the findings from the study are not interpreted as forecast financial information under ASIC Regulatory Guide 170, Proteomics International has agreed to retract that Announcement. In retracting that Announcement, Proteomics International notes that investors should not rely on the information as a basis for making an investment decision about its shares. Importantly, shares in Proteomics International have not traded since release of the Announcement. The economic health benefit study was undertaken to support the Company's application for a unique reimbursement code for PromarkerD in the US, and was conducted by independent consultant, Boston Healthcare Associates.

02/07/2021

The Company requests an extension to the voluntary suspension of its securities pending the release of an announcement regarding the presentation given at the American Diabetes Association's 81st Scientific Sessions, 25-29 June 2021. The Company estimates that it will be able to lodge an announcement on or before the commencement of trading on Tuesday, 6 July 2021.

02/07/2021

The securities of Proteomics International Laboratories Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of PIQ, pending the release of the presentation given at the American Diabetes Association's 81st Scientific Sessions, 25-29 June 2021.

29/06/2021

listed entity carried for record purposes only

16/04/2015
OFX Transferring Money Internationally to Free

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    25/06/2020Roger Moore90,000$0.409$36,819
    25/06/2020Paul House120,000$0.410$49,200
    24/06/2020Richard Lipscombe37,500$0.410$15,375
    12/09/2017Roger Moore65,000$0.200$13,000
    30/12/2016Roger Moore12,000$0.250$3,000

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Terry SweetNon Exec Chairman16/04/2014
    Richard LipscombeManaging Director16/04/2014
    Jacqueline GrayCFO10/06/2021
    Paul HouseNon Exec Director22/11/2017
    Roger MooreNon Exec Director14/10/2016

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    John DunlopNon Exec Director16/04/201422/11/2018
    Bill ParkerNon Exec Director16/04/201428/06/2016
    James MosesExecutive Director16/10/201528/06/2016

    Date of first appointment, title may have changed.